A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.

ABSTRACT: Globally, colorectal cancer (CRC) is the third most frequently occurring cancer. Progression on to an advanced metastatic malignancy (metCRC) is often indicative of poor prognosis, as the 5-year survival rates of patients decline rapidly. Despite the availability of many systemic therapies for the management of metCRC, the long-term efficacies of these regimens are often hindered by the emergence of treatment resistance due to intratumoral and intertumoral heterogeneity. Furthermore, not all systemic therapies have associated biomarkers that can accurately predict patient responses. Hence, a functional personalised oncology (FPO) approach can enable the identification of patient-specific combinatorial vulnerabilities and synergistic combinations as effective treatment strategies. To this e

SUBMITTER: Thng DKH 

PROVIDER: S-EPMC10899621 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature